BC Platforms raises $15m Series C financing led by IQVIA

– SWITZERLAND, Zürich –  BC Platforms, a world leader in genomic data management and analytics, today announced that it has closed a USD $15 million financing round led by IQVIA (NYSE: IQV) in conjunction with Debiopharm Innovation Fund and Tesi, Finnish venture capital and private equity company. As part of the collaboration, IQVIA and BC Platforms plan to launch new data-driven technologies, integrating complex clinical and genomic data, to benefit transformational research. IQVIA will have a designee on the BC Platforms’ Board of Directors.

The company also announced a new commercial collaboration with IQVIA.

IQVIA and BC Platforms have a shared vision to build a world-leading analytics platform to enable the pharmaceutical industry’s advancement of precision medicine, improving the efficiency of drug development and patient outcomes. BC Platforms technology will enhance IQVIA’s E360 Genomics – a scalable, privacy-preserving genotypic-phenotypic database solution – in supporting a federated data network of genomic related analytics designed to protect patient privacy.

BC Platforms will use the fundraising proceeds to expand its global network of clinical and genomics data, delivering novel automated solutions to pharmaceutical companies. To date, the company has established partnerships with approximately 100 enterprise-level healthcare systems and biobanks globally in 25 countries and has recently established an entity in Singapore to spearhead its growing activities in Asia.

Tero Silvola, CEO at BC Platforms, said: “IQVIA and BC Platforms aim to combine genomic and clinical data assets around the world. IQVIA´s E360 Genomics is built on patented techniques that allow us to build data access without compromising data privacy and security. Together with IQVIA´s deep healthcare expertise in managing and curating real-world data, we believe that we can accelerate precision medicine initiatives for patient benefits. This funding and commercial collaboration will help accelerate our growth in serving healthcare and Life Science customers as well as connecting data partners in a global, interoperable federated network.’

Rob Kotchie, President, Real World Solution, IQVIA, said: “Drawing insights from integrated clinical-genomics data is a growing need of our life science and healthcare customers. Through the combination of BC Platforms technologies – which automates the workflow from genomic instruments to actionable insights – with IQVIAs leading real-world technologies platform, we can enable customers to conduct novel research and discover new insights to advance healthcare.”

Tom Gibbs, Director at Debiopharm, commented: ‘”We are dedicated supporters of innovation and believe that digital health and data accessibility are going to be key drivers of future healthcare research and development. We are delighted to be supporting BC Platforms, a leader in the field of genomic data management, in the next stage of their expansion and are excited by the potential of this collaboration with IQVIA.”

About BC Platforms

BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. The company has launched and opened a global network of biobanks, known as BCRQUEST.COM, to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms’ vision is to build the world’s leading analytics platform for healthcare and industry by 2020, providing access to diverse genomic and clinical data and samples from more than 5 million subjects consolidated from a global network of biobanks.

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Zurich, Switzerland, research and development in Espoo, Finland, and sales and marketing in London, Boston, Vancouver and Singapore.

For more information: https://www.bcplatforms.com

About IQVIA

IQVIA (NYSE: IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 65,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

For more information: https://www.iqvia.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.